Lamivudine

Generic Name: Lamivudine

Brand Names: Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₁N_₃O_₃S

CAS Number: 134678-17-4

Unique Ingredient Identifier: 2T8Q726O95

Background: A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication: For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions: Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

Phase 4

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 200

Registration Number: NCT00002179

Locations: 🇺🇸
LAC - USC Med Ctr, Los Angeles, California, United States
🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr / Infect Dis, Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Med Ctr - East Campus, Boston, Massachusetts, United States

and more 14 locations

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2014-04-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1710

Registration Number: NCT00000922

Locations: 🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States
🇺🇸
Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸
Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York, New York, United States

and more 14 locations

Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 280

Registration Number: NCT00000831

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina, United States
🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

and more 37 locations

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 256

Registration Number: NCT00000838

Locations: 🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸
Santa Clara Valley Med. Ctr., San Jose, California, United States
🇺🇸
San Mateo County AIDS Program, San Mateo, California, United States

and more 29 locations

A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 500

Registration Number: NCT00001084

Locations: 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸
Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium, San Jose, California, United States
🇺🇸
Stanford Univ Med Ctr, Stanford, California, United States

and more 42 locations

The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 105

Registration Number: NCT00001067

Locations: 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸
Ucsd, Avrc Crs, San Diego, California, United States
🇺🇸
Stanford CRS, Palo Alto, California, United States

and more 10 locations

Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 55

Registration Number: NCT00004855

Locations: 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸
Denver Dept of Health and Hosps, Denver, Colorado, United States
🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States

and more 20 locations

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-06-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 900

Registration Number: NCT00000919

Locations: 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸
Marin County Specialty Clinic, San Rafael, California, United States
🇺🇸
Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States

and more 77 locations

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-05-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1125

Registration Number: NCT00013520

Locations: 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, St. Louis, Missouri, United States

and more 57 locations

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-05-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000918

Locations: 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸
Cook County Hosp, Chicago, Illinois, United States

and more 36 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy